Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C27H24FN3O |
| Molecular Weight | 425.4974 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OCCC#CC1=NC(=C(N1CCCC2=CC=CC=C2)C3=CC=NC=C3)C4=CC=C(F)C=C4
InChI
InChIKey=QSUSKMBNZQHHPA-UHFFFAOYSA-N
InChI=1S/C27H24FN3O/c28-24-13-11-22(12-14-24)26-27(23-15-17-29-18-16-23)31(25(30-26)10-4-5-20-32)19-6-9-21-7-2-1-3-8-21/h1-3,7-8,11-18,32H,5-6,9,19-20H2
| Molecular Formula | C27H24FN3O |
| Molecular Weight | 425.4974 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
4.4 ng/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/12723461/ |
0.25 mg/kg single, oral dose: 0.25 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
RWJ-67657 plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
32.3 ng/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/12723461/ |
1 mg/kg single, oral dose: 1 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
RWJ-67657 plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
203 ng/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/12723461/ |
3 mg/kg single, oral dose: 3 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
RWJ-67657 plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
363 ng/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/12723461/ |
5 mg/kg single, oral dose: 5 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
RWJ-67657 plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1283 ng/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/12723461/ |
10 mg/kg single, oral dose: 10 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
RWJ-67657 plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
2363 ng/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/12723461/ |
20 mg/kg single, oral dose: 20 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
RWJ-67657 plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
2568 ng/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/12723461/ |
30 mg/kg single, oral dose: 30 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
RWJ-67657 plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
542 ng/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/12723461/ |
10 mg/kg single, oral dose: 10 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
RWJ-67657 plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
14.3 ng × h/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/12723461/ |
0.25 mg/kg single, oral dose: 0.25 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
RWJ-67657 plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
61.1 ng × h/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/12723461/ |
1 mg/kg single, oral dose: 1 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
RWJ-67657 plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
320 ng × h/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/12723461/ |
3 mg/kg single, oral dose: 3 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
RWJ-67657 plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
718 ng × h/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/12723461/ |
5 mg/kg single, oral dose: 5 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
RWJ-67657 plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
2832 ng × h/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/12723461/ |
10 mg/kg single, oral dose: 10 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
RWJ-67657 plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
8941 ng × h/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/12723461/ |
20 mg/kg single, oral dose: 20 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
RWJ-67657 plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
12331 ng × h/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/12723461/ |
30 mg/kg single, oral dose: 30 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
RWJ-67657 plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1904 ng × h/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/12723461/ |
10 mg/kg single, oral dose: 10 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
RWJ-67657 plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1.3 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/12723461/ |
0.25 mg/kg single, oral dose: 0.25 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
RWJ-67657 plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
2.8 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/12723461/ |
1 mg/kg single, oral dose: 1 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
RWJ-67657 plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
5.3 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/12723461/ |
3 mg/kg single, oral dose: 3 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
RWJ-67657 plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
6.9 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/12723461/ |
5 mg/kg single, oral dose: 5 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
RWJ-67657 plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
5.1 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/12723461/ |
10 mg/kg single, oral dose: 10 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
RWJ-67657 plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
7.7 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/12723461/ |
20 mg/kg single, oral dose: 20 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
RWJ-67657 plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
5.3 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/12723461/ |
30 mg/kg single, oral dose: 30 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
RWJ-67657 plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
5.4 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/12723461/ |
10 mg/kg single, oral dose: 10 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
RWJ-67657 plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
PubMed
| Title | Date | PubMed |
|---|---|---|
| The beta3-adrenoceptor agonist 4-[[(Hexylamino)carbonyl]amino]-N-[4-[2-[[(2S)-2-hydroxy-3-(4-hydroxyphenoxy)propyl]amino]ethyl]-phenyl]-benzenesulfonamide (L755507) and antagonist (S)-N-[4-[2-[[3-[3-(acetamidomethyl)phenoxy]-2-hydroxypropyl]amino]-ethyl]phenyl]benzenesulfonamide (L748337) activate different signaling pathways in Chinese hamster ovary-K1 cells stably expressing the human beta3-adrenoceptor. | 2008-11 |
|
| Long-term but not short-term p38 mitogen-activated protein kinase inhibition improves cardiac function and reduces cardiac remodeling post-myocardial infarction. | 2008-06 |
|
| Suppression of HIV-1 viral replication and cellular pathogenesis by a novel p38/JNK kinase inhibitor. | 2004-03-26 |
|
| Strong inhibition of TNF-alpha production and inhibition of IL-8 and COX-2 mRNA expression in monocyte-derived macrophages by RWJ 67657, a p38 mitogen-activated protein kinase (MAPK) inhibitor. | 2004 |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 11:19:32 GMT 2025
by
admin
on
Wed Apr 02 11:19:32 GMT 2025
|
| Record UNII |
MXN26D3ZUN
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID40175867
Created by
admin on Wed Apr 02 11:19:32 GMT 2025 , Edited by admin on Wed Apr 02 11:19:32 GMT 2025
|
PRIMARY | |||
|
215303-72-3
Created by
admin on Wed Apr 02 11:19:32 GMT 2025 , Edited by admin on Wed Apr 02 11:19:32 GMT 2025
|
PRIMARY | |||
|
MXN26D3ZUN
Created by
admin on Wed Apr 02 11:19:32 GMT 2025 , Edited by admin on Wed Apr 02 11:19:32 GMT 2025
|
PRIMARY | |||
|
RWJ-67657
Created by
admin on Wed Apr 02 11:19:32 GMT 2025 , Edited by admin on Wed Apr 02 11:19:32 GMT 2025
|
PRIMARY | Selective p38α and p38β inhibitor (IC50 values are 1 and 11 μM respectively) that displays no activity at p38γ, p38δ and a range of other kinases. Potently inhibits TNF-α and IL-1β release (IC50 values are 3 and 11 nM respectively) and suppresses HIV-1 replication in T cells in vitro. Displays cardioprotective and anti-inflammatory activity in vivo. Orally active. | ||
|
3008319
Created by
admin on Wed Apr 02 11:19:32 GMT 2025 , Edited by admin on Wed Apr 02 11:19:32 GMT 2025
|
PRIMARY | |||
|
CHEMBL190333
Created by
admin on Wed Apr 02 11:19:32 GMT 2025 , Edited by admin on Wed Apr 02 11:19:32 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
RWJ 67657 (4-[4-(4-fluorophenyl)-1-(3-phenylpropyl)-5-(4-pyridinyl)-1H-imidazol -2-yl]-3-butyn-1-ol) inhibited the release of TNF-alpha by lipopolysaccharide (a monocyte stimulus)-treated human peripheral blood mononuclear cells with an IC(50) of 3 nM, as well as the release of TNF-alpha from peripheral blood mononuclear cells treated with the superantigen staphylococcal enterotoxin B (a T cell stimulus), with an IC(50) value of 13 nM.
|
